A phase 3 trial evaluates the efficacy of mezigdomide plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in ...
The Phase III EPCORE DLBCL-1 met one of the two endpoints, with Genmab set to discuss next steps with global regulatory authorities.
CHICAGO — The benefit observed with lorlatinib (Lorbrena) in 5-year follow-up data from the CROWN trial corresponds to the longest progression-free survival (PFS) reported for any targeted therapy in ...
In treatment-naive patients with metastatic uveal melanoma who have HLA-A2 negativity, darovasertib plus crizotinib improves ...
Provident Financial (PFS Quick Quote PFS - Free Report) closed the last trading session at $16.69, gaining 4.3% over the past four weeks, but there could be plenty of upside left in the stock if short ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results